JANX Profile
Janux Therapeutics, Inc. is an innovative biopharmaceutical company dedicated to developing cutting-edge cancer therapies using its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. The company's approach focuses on harnessing the power of the immune system to target and destroy cancer cells. The TRACTr platform is designed to create therapeutics that selectively engage and activate T cells in the tumor microenvironment, thereby enhancing the body's natural ability to fight cancer.
Janux's lead product candidates, currently in preclinical or discovery stages, include targets such as prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). These targets are implicated in various cancer types, and Janux's TRACTr candidates are being developed to address these cancers with precision and efficacy. The company's approach aims to offer targeted treatment options for patients with challenging cancer types and unmet medical needs.
In addition to its TRACTr platform, Janux is advancing its Tumor Activated Immunomodulator (TRACIr) technology. This costimulatory bispecific product candidate is designed to enhance T cell activity by targeting programmed death-ligand 1 (PD-L1) and CD28. By modulating the immune response, TRACIr aims to improve the anti-tumor activity of T cells, offering a potential advancement in cancer immunotherapy. The company’s EGFR-TRACTr product is specifically designed to target EGFR, a common target in oncology, and to provide new therapeutic options for cancers associated with this receptor.
Founded in 2017 and headquartered in La Jolla, California, Janux Therapeutics has quickly emerged as a leader in the development of next-generation cancer therapies. The company’s commitment to leveraging its proprietary technologies to tackle complex cancer challenges reflects its strategic focus on innovation and patient outcomes. Through its robust pipeline and advanced therapeutic platforms, Janux is positioned to make significant contributions to the field of oncology and to offer new hope for patients facing difficult-to-treat cancers.
|
